MS
RETA

Maven Securities’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Maven Securities’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-294,300
Closed -$50.7M – 1266
2023
Q3 		$50.7M Buy
+294,300
New +$44.3M 0.58% 28

Maven Securities's RETA Position: Q1 2020 in Review

Maven Securities sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2020, closing a stake of 50,000 shares — an estimated $10.3M sold.

Maven Securities first reported a position in RETA in Q4 2019 and held it in 1 quarter. The position peaked at $10.3M in Q4 2019. 214 funds tracked by Wall St. Rank hold RETA as of Q1 2020.

  • Maven Securities reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2020 after selling out during the quarter.
  • Maven Securities sold 50,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2020, an estimated $10.3M.
  • Maven Securities first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 1 quarter.
  • Maven Securities's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $10.3M in Q4 2019.
  • 214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2020.

Based on Maven Securities's 13F filing for Q1 2020, filed 15 May 2020.